Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Full-dose versus prophylactic anticoagulation in severe COVID-19
RBR-949z6vPhase 2Recruiting
- Sponsor
- Faculdade de Medicina de Ribeirão Preto
- Start
- May 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enoxaparin and heparin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Faculdade de Medicina de Ribeirão Preto. Started May 2020; status: recruiting.
02
Drugs
enoxaparinheparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on RBR-949z6v.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-949z6v.